Caliber Associates Recruits Chief Medical Officer for NextCure
February 1, 2021 – Over the past few months, numerous healthcare organizations have turned to executive search firms to find new chief medical officers. In the era of COVID-19 this is likely to be another burgeoning area for executive search firms.
San Diego, CA- based Caliber Associates recently placed former NexImmune executive Han Myint as the new chief medical officer for NextCure, a clinical-stage biopharmaceutical company. Steve Hochberg, CEO and founder of Caliber Associates, led the assignment. “We are very excited that Han has joined the NextCure team,” said Michael Richman, president and CEO of NextCure. “We believe the depth of his expertise in oncology product development will prove instrumental in the advancement of our product pipeline. Han’s strong industry track record is highlighted by his involvement in the development of multiple U.S. Food and Drug approved products.”
Dr. Myint has over 20 years of experience in both academia and the biopharma industry. Before joining NextCure, he was chief medical officer at NexImmune, a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies. Prior to that, he was vice president of global medical affairs and the myeloid diseases lead at Celgene. Dr. Myint’s work in myeloid diseases at Celgene contributed to a number of FDA approvals, successful launches of those products and high-impact publications. Prior to joining the biopharma industry, Dr. Myint practiced medicine specializing in hematological oncology and conducted clinical and laboratory research at multiple prestigious academic institutions in the U.K. and U.S. including Rush University Medical Center in Chicago and University of Colorado, Denver. Dr. Myint, professor of medicine, built a FACT-accredited and Center of Excellence-Designated Stem Cell Transplant Program at the University of Colorado, Denver.
Leadership in a Post-Covid World
In this brand new episode of “Talent Talks,” Hunt Scanlon Media host Rob Adams is joined by Steve Hochberg, CEO of Caliber Associates. In this podcast, Mr. Hochberg discusses how COVID-19 has changed leadership expectations and then shares how leaders can promote and sustain culture as employees return to the workplace. Listen now!
“I’m thrilled to join NextCure at this important time in the company’s growth,” said Dr. Myint. “I believe that the company, through its powerful discovery platform, has created a pipeline of novel immunomedicines, including NC318 and NC410, with the potential to have a significant impact in cancer treatment.”
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through its proprietary FIND-IO platform, the company studies various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. NextCure’s initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies.
Life Sciences Recruiters
Caliber Associates, founded in 1988, is focused exclusively on the life sciences sector. The firm’s leaders are highly experienced search professionals and biopharmaceutical executives who bring more than 70 years of industry experience. Caliber Associates has partnered with over 150 leading companies and has completed upwards of 700 searches, placing strategic leaders with broad therapeutic and functional reach. The firm has offices in San Diego, metro New York and Boston/Cambridge, MA.
Among the roles that the firm has recently filled include: chief scientific officer for GentiBio, vice president of project management at Locanabio and CEO for Caraway Therapeutics.
Mr. Hochberg focuses on recruiting CEOs, board members, C-level and strategic teams for emerging life science companies and global biopharmaceutical companies. He has assembled a small team of highly experienced, results driven search professionals. Prior to his search career, he held strategic human resources roles with Rhône-Poulenc Rorer, FMC Corp. and Shell Oil Co.
Contributed by Scott A. Scanlon, Editor-in-Chief; Dale M. Zupsansky, Managing Editor; and Stephen Sawicki, Managing Editor – Hunt Scanlon Media
